Emergence of a strain of methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin 7 months after treatment with glycopeptide antibiotics  by Sy, Cheng Len et al.
Journal of Microbiology, Immunology and Infection (2016) 49, 142e145Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comCASE REPORTEmergence of a strain of methicillin-
resistant Staphylococcus aureus with
decreased susceptibility to vancomycin 7
months after treatment with glycopeptide
antibioticsCheng Len Sy a, Susan Shin-Jung Lee a,b, Kuan-Sheng Wu a,b,
Hung-Chin Tsai a,b, Yung-Ching Liu c, Yao-Shen Chen a,b,*a Section of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital,
Kaohsiung, Taiwan
b National Yang-Ming University, Taipei, Taiwan
c Section of Infectious Diseases, Shuang-Ho Hospital, Taipei Medical University and School of Medicine,
Taipei Medical University, Taipei, TaiwanReceived 31 March 2013; received in revised form 28 May 2013; accepted 19 July 2013
Available online 26 September 2013KEYWORDS
Daptomycin;
Glycopeptide;
Resistance;
Staphylococcus
aureus;
Vancomycin* Corresponding author. Section of
ment of Medicine, Kaohsiung Vetera
siung, Taiwan.
E-mail address: yschen@vghks.gov
1684-1182/$36 Copyright ª 2013, Taiw
CC BY-NC-ND license (http://creative
http://dx.doi.org/10.1016/j.jmii.2013This case report describes amethicillin-resistant Staphylococcus aureus isolated repeatedly from
the blood of a patientwith community-acquired endocarditis who developed a four-fold increase
in the minimal inhibitory concentration of vancomycin and daptomycin 7 months after his last
exposure to glycopeptide antibiotics. This is contrary to the expected situation in which antimi-
crobial resistance tends to decrease after a patient is no longer exposed to vancomycin.
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.07.006Introduction
Methicillin-resistant Staphylococcus aureus (MRSA)
emerged in the 1960s,1 and gradually became an endemic
pathogen in hospital settings in the 1980s. This led to the
extensive use of vancomycin for the treatment of MRSA
infections. MRSA with reduced vancomycin susceptibilityhed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Emergence of delayed resistance in MRSA 143appeared in the 1990s, and tends to disappear following
cessation of vancomycin therapy.2 The current report de-
scribes a strain of MRSA, repeatedly isolated from the blood
of a patient with community-acquired bacterial endo-
carditis, which exhibited a delayed increase in the mini-
mum inhibition concentration (MIC) of vancomycin 200 days
following treatment with vancomycin and teicoplanin.Case report
A 45-year-old male intravenous drug user was admitted to
Kaohsiung Veterans General Hospital, Taiwan in March,
2007 with MRSA infective endocarditis and lumbar spine
osteomyelitis. He was treated with vancomycin for 3 days
followed by a 24-day, intermittent course of teicoplanin.
During this period, the MIC of vancomycin rose from 2 mg/
dL to 4 mg/dL. Teicoplanin was switched to linezolid on
Day 19 due to persistence of fever. There were no glyco-
peptide exposures since then. Blood cultures were ob-
tained as an outpatient at 1e3 week intervals. MRSA was
re-isolated on the Day 110. He was treated for 110 days
with oral trimethoprimesulfamethoxazole and chloram-
phenicol. He was readmitted on the Day 257 because
of fever. MRSA with an MIC of 8 mg/dL was isolated
from his blood. There was no concurrent infection with
vancomycin-resistant enterococci. He was treated with
linezolid and chloramphenicol for 23 days and then
switched to trimethoprimesulfamethoxazole and moxi-
floxacin until Day 337. Blood cultures continued to remain
sterile after Day 264. The patient was not screened for
colonization with MRSA or vancomycin-resistant entero-
cocci. A preliminary report of this case was published3MIC (µg/mL)
Vancomycin 2 4 4 4
Teicoplanin a 0.75 1.5 1.5 1
Rifampin 0.5 4 4 4
Gentamicin 16 16 16 16
TMP 0.5 0.5 0.5 0.5
Moxifloxacin 0.25 0.25 0.25 0.25
Daptomycin 1 2 2 2
a MIC determined by E-test
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Figure 1. Course of treatment of a patient with bacterial endo
(MICs/dL) to 10 antibiotics of a methicillin-resistant strain of Sta
MarcheNovember 2007. MIC determined by the E-test method.
SMX Z trimethoprimesulfamethoxazole.prior to noting the four-fold rise in the MIC of vancomy-
cin and daptomycin on Day 257 and knowledge of the
follow-up by Day 110 day.Laboratory studies
Blood culture isolates obtained at Day 0, Day 47, Day 55,
Day 110, and Day 257 were stored at 80C. Following
reconstitution antibiotic susceptibility and genetic profiles
were performed on all the isolates together with S. aureus
ATCC 29213. The MICs for vancomycin, daptomycin,
rifampin, gentamicin, trimethoprimesulfamethoxazole,
and moxifloxacin were determined, in duplicate, by broth
microdilution using Sensititre custom designed plates for
staphylococci (Trek Diagnostics, East Grinstead, West Sus-
sex, UK). The MIC for teicoplanin was determined by the E-
test (AB Biodisk, bioMe´rieux SA, Marcy l’Etoile, France).
Pulsed field gel electrophoresis (PFGE) was conducted using
standard DNA extraction methods. Lambda ladder PFG
marker (New England Biolabs, Schwalbach, Germany) was
used as fragment size marker. The type IV staphylococcal
cassette chromosome mec and Pantoneleukocidin genes
were determined as previously described.3 Multilocus
sequence typing (MLST) was performed as described by
Enright et al.4 The MLST sequences were submitted to the
MLST database (http://www.mlst.net/). Spa typing was
performed using methods described by Harmsen et al.5
The antimicrobial susceptibility results are shown in
Fig. 1. The key findings were a four-fold increase in the MICs
of vancomycin, teicoplanin, and daptomycin without sig-
nificant changes in the MICs of the other antibiotics during
the study period. All isolates were found to be identical by8
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Figure 2. Pulsed-field gel electrophoresis patterns of
methicillin-resistant Staphylococcus aureus isolated from the
blood of a patient with bacterial endocarditis (Isolates 1e5).
Lane M Z lambda ladder pulsed-field gel marker.
144 C.L. Sy et al.PFGE typing (Fig. 2). The isolate contained the type IV
staphylococcal cassette chromosome mec, Pan-
toneleukocidin genes, ST type 59, and spa type t437.
Discussion
Decreased susceptibility to vancomycin following pro-
longed exposure to subinhibitory concentrations is attrib-
uted to the development of tolerance and decreased
autolysis.6,7 MRSA strains tend to lose resistant sub-
populations after a week of serial passage in a drug-free
media.3 Our patient received vancomycin for 3-days and
teicoplanin for 24 days. Nevertheless, the MICs of vanco-
mycin, teicoplanin, and daptomycin continued to rise up to
254 days after the last dose of vancomycin and almost 200
days after the last exposure to teicoplanin. He was
followed-up regularly in the outpatient department and
was exposed only to linezolid, chloramphenicol, and tri-
methoprimesulfamethoxazole. Vancomycin trough level
assays were not available at our institution during the time
of the study. The PFGE and genetic studies provide strong
evidence of clonal identity of all the isolates. Thus the
phenomenon cannot be explained by superinfection with
new strains of MRSA.Prolonged exposure to teicoplanin appears to be the
most likely explanation for the reduced susceptibility to
vancomycin. Shlaes and Shlaes8 demonstrated that
vancomycin-resistant MRSA mutant may appear after
exposure to another glycopeptide. An unexpected finding
was the sequential increase in resistance to daptomycin
after a remote exposure to glycopeptides. A relationship
between resistance to daptomycin and vancomycin has
been described.9 It has been postulated that the thickened
wall of vancomycin-intermediate S. aureus may impede the
access of daptomycin to the cell membrane surface.10 The
combined increase in resistance to glycopeptides and
daptomycin after remote exposure to vancomycin has not,
to our knowledge, been previously described. A reversion of
resistance is generally expected after removal of the
selecting agent; this case demonstrates that persistence of
resistant clones with paradoxical progression of resistance
is possible, and is a reason for concern. It is not known
whether exposure to other antistaphylococcal antibiotics
may have played a role.
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